&lt;p&gt;Emerging Targets of Immunotherapy in Gynecologic Cancer&lt;/p&gt;

Cheng, Hongyan; Zong, Liju; Kong, Yujia; Gu, Yu; Yang, Junjun; Xiang, Yang

doi:10.2147/ott.s282530

Cited by 7 publications

(5 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TIM-3 is a type I transmembrane protein expressed mainly on CD8 + and CD4 + T cells, DCs, monocytes, NK cells, and Tregs ( 22 ). GAL-9 is a ligand of TIM-3.…”

Section: Discussionmentioning

confidence: 99%

Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia

Cheng¹,

Zong²,

Yu³

et al. 2023

Pathol. Oncol. Res.

Self Cite

View full text Add to dashboard Cite

Objectives: To evaluate the expression of emerging immune targets in the tumor-infiltrating immunocytes (TIIs) of human gestational trophoblastic neoplasia (GTN) specimens, and to analyze the correlation between the expression patterns and prognosis of GTN patients.Methods: Between January 2008 and December 2017, patients who were diagnosed histologically with GTN were included in this study. The expression densities of LAG-3, TIM-3, GAL-9, PD-1, CD68, CD8, and FOXP3 in the TIIs were assessed independently by two pathologists blinded to clinical outcomes. The expression patterns and correlation with patient outcomes were analyzed to identify prognostic factors.Results: We identified 108 patients with GTN, including 67 with choriocarcinoma, 32 with placental site trophoblastic tumor (PSTT), and 9 with epithelioid trophoblastic tumor (ETT). Almost all GTN patients showed expression of GAL-9, TIM-3, and PD-1 in TIIs (100%, 92.6%, and 90.7%, respectively); LAG-3 was expressed in 77.8% of the samples. The expression densities of CD68 and GAL-9 were significantly higher in choriocarcinoma than that in PSTT and ETT. The TIM-3 expression density in choriocarcinoma was higher than that in PSTT. In addition, the expression density of LAG-3 in the TIIs of choriocarcinoma and PSTT was higher than that in ETT. There was no statistical difference in the expression pattern of PD-1 among different pathological subtypes. The positive expression of LAG-3 in tumor TIIs was a prognostic factor for disease recurrence, and patients with positive expression of LAG-3 in the TIIs had poorer disease-free survival (p = 0.026).Conclusion: Our study evaluated the expression of immune targets PD-1, TIM-3, LAG-3, and GAL-9 in the TIIs of GTN patients and found that they were widely expressed but not associated with patients’ prognoses, excepting the positive expression of LAG-3 was a prognostic factor for disease recurrence.

show abstract

“…TIM-3 is a type I transmembrane protein expressed mainly on CD8 + and CD4 + T cells, DCs, monocytes, NK cells, and Tregs ( 22 ). GAL-9 is a ligand of TIM-3.…”

Section: Discussionmentioning

confidence: 99%

Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia

Cheng¹,

Zong²,

Yu³

et al. 2023

Pathol. Oncol. Res.

Self Cite

View full text Add to dashboard Cite

show abstract

“…This finding addresses the need for effective treatment in advanced EC patients. However, an important concern for healthcare decision-makers, physicians, and patients is that new alternative treatment options, such as immunotherapy and molecularly targeted therapies, often come at a higher cost than previously used therapies, leading to sustained increases in healthcare costs ( 36 , 37 ). The price of new anticancer drugs should not only be reasonable and affordable for patients to easily access treatment but also sustainable for the national healthcare system and pharmaceutical companies.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer

You,

Zeng,

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundA recent phase III clinical trial (NCT03981796) evaluated the efficacy and safety of dostarlimab combined with carboplatin-paclitaxel (DOS-CP) compared to placebo combined with carboplatin-paclitaxel (PLB-CP) as a first-line treatment for advanced endometrial cancer (EC). The NCT03981796 trial demonstrated that DOS-CP significantly improved progression-free survival and overall survival of patients with advanced EC while maintaining an acceptable safety profile. However, DOS-CP is expensive and its cost-effectiveness has not been evaluated. This study aims to evaluate the cost-effectiveness of DOS-CP compared to PLB-CP as a first-line treatment for advanced EC from the perspective of the Chinese healthcare system.MethodsA Markov model with three health states was developed to evaluate the cost-effectiveness of DOS-CP as a first-line treatment for advanced EC. Clinical efficacy data were derived from the NCT03981796 trial, and drug costs were determined based on national tender prices. Other costs and utility values were obtained from published literature. The outcomes assessed included total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). The robustness of the model was assessed through one-way sensitivity analysis and probabilistic sensitivity analysis.ResultsIn comparison to PLB-CP, the ICER of DOS-CP was $98,276.61/QALY for the overall population, $53,063.61/QALY for the dMMR subgroup, and $124,088.56/QALY for the pMMR subgroup. All of these ICER values were higher than the willingness-to-pay threshold of $38,201 per QALY. The most important variable that affected the results of the model was the discount rate, the cost of dostarlimab, and the utility value for progressive disease.ConclusionFrom the perspective of the Chinese healthcare system, DOS-CP is unlikely to be a cost-effective first-line treatment option for advanced EC.

show abstract

“…New therapeutic interventions, such as immunotherapy and molecularly targeted drugs, develop new ways to treat and improve the survival and quality of life of patients (Cheng et al, 2020). However, these new treatments are expensive, contributing to China's unsustainable rise in healthcare costs (Xiong et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China

Zheng

Liu²,

Xu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Aims: This study aimed to evaluate the cost-effectiveness of lenvatinib plus pembrolizumab (LP) vs. chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China.Methods: A lifetime of partitioned survival Markov was used to evaluate the overall lifetime, total costs, quality adjusted life years (QALYs), and incremental cost effectiveness ratio (ICER) across a 10-years time horizon in the study 309–KEYNOTE-775 clinical trial. Direct costs and utility values were gathered from available literature. The willingness to pay (WTP) was defined at $37,663.26 per QALY. Sensitivity analyses were carried out to determine the model’s uncertainty.Results: According to the baseline analysis, the LP group gained 4.02 total life years and 3.13 QALYs for $93,496.69, whereas the chemotherapy group gained 2.86 total life years and 2.24 QALYs for $30,578.04. LP versus chemotherapy resulted in an incremental cost of $62,918.65, with an ICER of $70,962.09/QALY, which was higher than China’s WTP threshold ($37,663.26/QALY). The ICERs were most sensitive to the cost of pembrolizumab and the cycle of LP delivered, according to the sensitivity analysis. However, changing the range of those parameters has no influence on the model’s results.Conclusion: Our present analysis suggests that LP treatment is not cost-effective for patients with previously treated mismatch repair proficient advanced endometrial cancer. However, LP treatment may be a cost-effective treatment option if the price is reduced.

show abstract

<p>Emerging Targets of Immunotherapy in Gynecologic Cancer</p>

Cited by 7 publications

References 103 publications

Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia

Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China

Contact Info

Product

Resources

About